Taken together, these findings indicate that targeting TNF-α or specifically the pro-tumor immunosuppressive TAMs that produce TNF-α may represent a promising therapeutic strategy to counteract the immunosuppressive microenvironment and improve treatment outcomes in PC. This evidence concerns the gene TNF and pachyonychia congenita.